Erratum: T cells from patients with Parkinson's disease recognize α-synuclein peptides (Nature (2017) 546 (656-661) DOI: 10.1038/nature22815);T cells from patients with Parkinson's disease recognize α-synuclein peptides

Nature

Volumn 546, Issue 7660, 2017, Pages 656-661

  Sulzer, David ^a,b   Alcalay, Roy N ^b   Garretti, Francesca ^a   Cote, Lucien ^b   Kanter, Ellen ^a   Agin Liebes, Julian ^a   Liong, Christopher ^b   McMurtrey, Curtis ^c   Hildebrand, William H ^c   Mao, Xiaobo ^d,e   Dawson, Valina L ^d,e   Dawson, Ted M ^d,e   Oseroff, Carla ^f   Pham, John ^f   Sidney, John ^f   Dillon, Myles B ^f   Carpenter, Chelsea ^f   Weiskopf, Daniela ^f   Phillips, Elizabeth ^g,h   Mallal, Simon ^g,h   Peters, Bjoern ^f   Frazier, April ^f   Lindestam Arlehamn, Cecilia S ^f   Sette, Alessandro ^f   more..

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^g MURDOCH UNIVERSITY   (Australia)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUROMELANIN; HLA ANTIGEN; PEPTIDE FRAGMENT;

CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; GENETIC ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE; PROTEIN;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SUBSTANTIA NIGRA; AMINO ACID SEQUENCE; AUTOIMMUNITY; CHEMISTRY; FEMALE; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; AUTOIMMUNITY; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 85021661653     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23896     Document Type: Erratum

References (44)

1. Greenbaum, J. et al. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63, 325-335 (2011).
2. Hamza, T. H. et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42, 781-785 (2010).
3. Kannarkat, G. T. et al. Common genetic variant association with altered HLA Expression, synergy with pyrethroid exposure, and risk for Parkinson's Disease: an observational and case-control study. NPJ Parkinson's Dis. 1, 15002 (2015).
4. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
5. Marrack, P. & Kappler, J. W. Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb. Perspect. Med. 2, a007765 (2012).
6. Foix, C. & Nicolesco, J. Cérébrale: Les Noyauz Gris Centraux Et La Région Mésencephalo-Soue-Optique. SuiviD'Un Appendice Sur L'Anatomic Pathologique De La Maladie De Parkinson (Masson et Cie., 1925).
7. Cebrián, C., Loike, J. D. & Sulzer, D. Neuroinflammation in Parkinson's disease animal models: a cell stress response or a step in neurodegeneration? Curr. Top. Behav. Neurosci. 22, 237-270 (2015).
8. Brochard, V. et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119, 182-192 (2009).
9. Wissemann, W. T. et al. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am. J. Hum. Genet. 93, 984-993 (2013).
10. Cebrián, C. et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun. 5, 3633 (2014).
11. Mor, F., Quintana, F., Mimran, A. & Cohen, I. R. Autoimmune encephalomyelitis and uveitis induced by T cell immunity to self β -synuclein. J. Immunol. 170, 628-634 (2003).
12. Theodore, S., Cao, S., McLean, P. J. & Standaert, D. G. Targeted overexpression of human α -synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67, 1149-1158 (2008).
13. Benner, E. J. et al. Nitrated α -synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 3, e1376 (2008).
14. Harms, A. S. et al. MHCII is required for α -synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 33, 9592-9600 (2013).
15. Vita, R. et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43, D405-D412 (2015).
16. Kim, K. S. et al. Proteolytic cleavage of extracellular α -synuclein by plasmin: implications for Parkinson disease. J. Biol. Chem. 287, 24862-24872 (2012).
17. Hossain, S. et al. Limited proteolysis of NACP/α -synuclein. J. Alzheimers Dis. 3, 577-584 (2001).
18. Fujiwara, H. et al. α -Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164 (2002).
19. Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of α -synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752 (2006).
20. Wang, W. et al. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α -synuclein. Proc. Natl Acad. Sci. USA 113, 9587-9592 (2016).
21. Kasai, T. et al. Cleavage of normal and pathological forms of α -synuclein by neurosin in vitro. Neurosci. Lett. 436, 52-56 (2008).
22. Li, W. et al. Aggregation promoting C-terminal truncation of α -synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 2162-2167 (2005).
23. Dufty, B. M. et al. Calpain-cleavage of α -synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725-1738 (2007).
24. Brahmachari, S. et al. Activation of tyrosine kinase c-Abl contributes to α -synuclein-induced neurodegeneration. J. Clin. Invest. 126, 2970-2988 (2016).
25. Hernandez, D. G., Reed, X. & Singleton, A. B. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J. Neurochem. 139, 59-74 (2016).
26. Martinez-Vicente, M. et al. Dopamine-modified α -synuclein blocks chaperonemediated autophagy. J. Clin. Invest. 118, 777-788 (2008).
27. Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired degradation of mutant α -synuclein by chaperone-mediated autophagy. Science 305, 1292-1295 (2004).
28. Orenstein, S. J. et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394-406 (2013).
29. Luk, K. C. et al. Pathological α -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
30. Atik, A., Stewart, T. & Zhang, J. α -Synuclein as a biomarker for Parkinson's disease. Brain Pathol. 26, 410-418 (2016).
31. Petrich de Marquesini, L. G.et al. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 53, 1451-1460 (2010).
32. Arif, S. et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β -cell death. Diabetes 60, 2112-2119 (2011).
33. Matheoud, D. et al. Parkinson's disease-related proteins PINK1 and Parkin repress mitochondrial antigen presentation. Cell 166, 314-327 (2016).
34. Alcalay, R. N. et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 138, 2648-2658 (2015).
35. Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E. & Lees, A. J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology 57, S34-S38 (2001).
36. Paul, S. et al. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J. Immunol. 191, 5831-5839 (2013).
37. Oseroff, C. et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J. Immunol. 185, 943-955 (2010).
38. McKinney, D. M. et al. Development and validation of a sample sparing strategy for HLA typing utilizing next generation sequencing. Hum. Immunol. 76, 917-922 (2015).
39. Paul, S. et al. A population response analysis approach to assign class II HLA-epitope restrictions. J. Immunol. 194, 6164-6176 (2015).
40. Sidney, J. et al. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Current Protoc. Immunol. 18, 18.13 (2013).
41. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).
42. Gulukota, K., Sidney, J., Sette, A. & DeLisi, C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267, 1258-1267 (1997).
43. Sidney, J. et al. Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population. J. Immunol. 185, 4189-4198 (2010).
44. Mao, X. et al. Pathological α -synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).